The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers

被引：25

作者：

Fabris, Martina ^{[1
]}

Quartuccio, Luca ^{[1
]}

Vital, Ed ^{[2
,3
]}

Pontarini, Elena ^{[1
]}

Salvin, Sara ^{[1
]}

Fabro, Cinzia ^{[1
]}

Zabotti, Alen ^{[1
]}

Benucci, Maurizio ^{[4
]}

Manfredi, Mariangela ^{[4
]}

Ravagnani, Viviana ^{[5
]}

Biasi, Domenico ^{[5
]}

Atzeni, Fabiola ^{[6
]}

Sarzi-Puttini, Piercarlo ^{[6
]}

Morassi, Pia ^{[7
]}

Fischetti, Fabio ^{[7
]}

Bazzicchi, Laura ^{[8
]}

Saracco, Marta ^{[9
]}

Pellerito, Raffaele ^{[9
]}

Cimmino, Marco ^{[10
]}

Carraro, Valeria ^{[11
]}

Semeraro, Angelo ^{[12
]}

Schiavon, Franco ^{[11
]}

Caporali, Roberto ^{[13
,14
]}

Bortolotti, Roberto ^{[15
]}

Govoni, Marcello ^{[16
]}

Fogolari, Federico ^{[1
]}

Tonutti, Elio ^{[1
]}

Bombardieri, Stefano ^{[8
]}

Emery, Paul ^{[2
,3
]}

De Vita, Salvatore ^{[1
]}

机构：

[1] Azienda Osped Univ Udine, Udine, Italy

[2] Univ Leeds, Leeds, W Yorkshire, England

[3] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England

[4] Osped San Giovanni di Dio, Florence, Italy

[5] Univ Verona, I-37100 Verona, Italy

[6] Osped L Sacco, Milan, Italy

[7] Osped Riuniti Trieste, Trieste, Italy

[8] Univ Pisa, Pisa, Italy

[9] Osped Mauriziano Umberto 1, Turin, Italy

[10] Univ Genoa, Genoa, Italy

[11] Univ Padua, Padua, Italy

[12] Osped Valle dItria, Martina Franca, Italy

[13] IRCCS Policlin San Matteo, Pavia, Italy

[14] Univ Pavia, I-27100 Pavia, Italy

[15] Santa Chiara Hosp, Trento, Italy

[16] Azienda Osped Univ Ferrara, Ferrara, Italy

来源：

ARTHRITIS AND RHEUMATISM | 2013年 / 65卷 / 01期

关键词：

CELL-ACTIVATING FACTOR; PRIMARY SJOGRENS-SYNDROME; ANTI-CCP; CLINICAL-RESPONSE; SYNOVIAL TISSUE; FACTOR GENE; DEPLETION; BAFF; POLYMORPHISM; EFFICACY;

D O I：

10.1002/art.37707

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Objective To investigate the polymorphisms in the promoter region of the B lymphocyte stimulator (BLyS) gene as markers of response to rituximab (RTX) in rheumatoid arthritis (RA). Methods The study was first conducted in 152 Italian RA patients and then replicated in an additional 117 RA patients (73 Italian, 44 British). The European League Against Rheumatism response criteria were used to evaluate the response rate at months 4 and 6 after the first cycle of RTX, by means of the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate; patients were classified according to the best response shown between months 4 and 6. BLyS promoter polymorphisms were analyzed by polymerase chain reaction followed by the analysis of the restriction fragments, BLyS promoter haplotypes were analyzed using the expectation-maximization algorithm, and BLyS serum levels were analyzed using enzyme-linked immunosorbent assay. Odds ratios (ORs) were calculated with 95% confidence intervals (95% CIs). Results The TTTT BLyS promoter haplotype appeared to be significantly associated with response to RTX only in the subset of seropositive patients (those positive for rheumatoid factor and/or anticyclic citrullinated peptide). The replication study confirmed that this association was limited to seropositive RA patients in whom treatment with antitumor necrosis factor (anti-TNF) agents had previously failed. In the whole series of seropositive patients in whom anti-TNF agents had previously failed, patients carrying the TTTT BLyS promoter haplotype were more prevalent in good responders (18 of 43 [41.9%]) than in moderate responders (20 of 83 [24.1%]) or in nonresponders (1 of 21 [4.8%]) (for good responders versus nonresponders, OR 14.4 [95% CI 1.77117.39], P = 0.0028). Furthermore, multivariate analysis selected the TTTT BLyS promoter haplotype as an independent marker of good response to RTX (for good responders versus nonresponders, OR 16.2 [95% CI 1.7152.5], P = 0.01; for good responders versus moderate responders and nonresponders combined, OR 3.1 [95% CI 1.27.8], P = 0.02). The relationship between BLyS polymorphisms and BLyS serum levels remained unclear. Conclusion BLyS promoter genotyping may be suitable for identifying seropositive RA patients who may have a good response to RTX after anti-TNF agents have failed.

引用

页码：88 / 97

页数：10

共 44 条

[1]

THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[2]

Association of the PTPN22 gene polymorphism with autoantibody positivity in Turkish rheumatoid arthritis patients [J].

Ates, A. ;

Karaaslan, Y. ;

Karatayli, E. ;

Ertugrul, E. ;

Aksaray, S. ;

Turkyilmaz, A. ;

Ozet, G. .

TISSUE ANTIGENS, 2011, 78 (01) :56-59

[3]

Synovial Tissue Heterogeneity and Peripheral Blood Biomarkers [J].

Bugatti, Serena ;

Manzo, Antonio ;

Bombardieri, Michele ;

Vitolo, Barbara ;

Humby, Frances ;

Kelly, Stephen ;

Montecucco, Carlomaurizio ;

Pitzalis, Costantino .

CURRENT RHEUMATOLOGY REPORTS, 2011, 13 (05) :440-448

[4]

B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response [J].

Cambridge, G. ;

Isenberg, D. A. ;

Edwards, J. C. W. ;

Leandro, M. J. ;

Migone, T-S ;

Teodorescu, M. ;

Stohl, W. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) :1011-1016

[5]

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment - Relationships with B cell depletion, circulating antibodies, and clinical relapse [J].

Cambridge, G ;

Stohl, W ;

Leandro, MJ ;

Migone, TS ;

Hilbert, DM ;

Edwards, JCW .

ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :723-732

[6]

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

[7]

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) [J].

Combe, B. ;

Landewe, R. ;

Lukas, C. ;

Bolosiu, H. D. ;

Breedveld, F. ;

Dougados, M. ;

Emery, P. ;

Ferraccioli, G. ;

Hazes, J. M. W. ;

Klareskog, L. ;

Machold, K. ;

Martin-Mola, E. ;

Nielsen, H. ;

Silman, A. ;

Smolen, J. ;

Yazici, H. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (01) :34-45

[8]

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis - Evidence for a pathogenetic role of B cells [J].

De Vita, S ;

Zaja, F ;

Sacco, S ;

De Candia, A ;

Fanin, R ;

Ferraccioli, G .

ARTHRITIS AND RHEUMATISM, 2002, 46 (08) :2029-2033

[9]

Treatment of rheumatoid arthritis with rituximab: An update and possible indications [J].

De Vita, Salvatore ;

Quartuccio, Luca .

AUTOIMMUNITY REVIEWS, 2006, 5 (07) :443-448

[10]

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].

Edwards, JCW ;

Szczepanski, L ;

Szechinski, J ;

Filipowicz-Sosnowska, A ;

Emery, P ;

Close, DR ;

Stevens, RM ;

Shaw, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581

← 1 2 3 4 5 →